NZ515685A - Use of riluzole for the treatment of multiple sclerosis - Google Patents

Use of riluzole for the treatment of multiple sclerosis

Info

Publication number
NZ515685A
NZ515685A NZ515685A NZ51568500A NZ515685A NZ 515685 A NZ515685 A NZ 515685A NZ 515685 A NZ515685 A NZ 515685A NZ 51568500 A NZ51568500 A NZ 51568500A NZ 515685 A NZ515685 A NZ 515685A
Authority
NZ
New Zealand
Prior art keywords
riluzole
treatment
multiple sclerosis
preparing
pharmaceutical composition
Prior art date
Application number
NZ515685A
Other languages
English (en)
Inventor
Chris Polman
Original Assignee
Vereniging Voor Christelijk Wetenschappelijk Onderwijs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging Voor Christelijk Wetenschappelijk Onderwijs filed Critical Vereniging Voor Christelijk Wetenschappelijk Onderwijs
Publication of NZ515685A publication Critical patent/NZ515685A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NZ515685A 1999-06-04 2000-06-02 Use of riluzole for the treatment of multiple sclerosis NZ515685A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99201788 1999-06-04
US17432800P 2000-01-04 2000-01-04
PCT/IB2000/000933 WO2000074676A1 (en) 1999-06-04 2000-06-02 Use of riluzole for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
NZ515685A true NZ515685A (en) 2002-12-20

Family

ID=56290027

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515685A NZ515685A (en) 1999-06-04 2000-06-02 Use of riluzole for the treatment of multiple sclerosis

Country Status (11)

Country Link
EP (2) EP1187612B1 (enExample)
JP (1) JP2003522121A (enExample)
AT (2) ATE287713T1 (enExample)
AU (1) AU777537B2 (enExample)
CA (1) CA2375874A1 (enExample)
DE (1) DE60017733T2 (enExample)
ES (1) ES2235896T3 (enExample)
NZ (1) NZ515685A (enExample)
PT (1) PT1187612E (enExample)
SI (1) SI1187612T1 (enExample)
WO (1) WO2000074676A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001376A2 (en) 1998-07-02 2000-01-13 Eisai Co., Ltd Pharmaceutical compositions and their uses for treatment of demyelinating disorders
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
IL136687A0 (en) * 2000-06-12 2001-06-14 Mor Research Applic Ltd Pharmaceutical composition for the treatment of multiple sclerosis
WO2005084377A2 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
ITMI20061274A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
WO2010113225A1 (en) * 2009-03-30 2010-10-07 Yutoku Pharmaceutical Industries Co., Ltd. Riluzole-containing transdermal patch
AU2015350142A1 (en) * 2014-11-21 2017-06-15 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
JP6827924B2 (ja) * 2014-11-26 2021-02-10 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． イブジラスト及びリルゾールの組み合わせを含む医薬および組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
AU7298196A (en) * 1995-10-25 1997-05-15 Janssen Pharmaceutica N.V. Infusions of neuroprotectants and perfluorochemicals
US6133258A (en) * 1995-11-05 2000-10-17 Yamanouchi Pharmaceutical Co., Ltd. Inhibitor of kainic acid neurotoxicity and pyridothiazine derivative
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
JP4120713B2 (ja) * 1997-09-04 2008-07-16 大塚製薬株式会社 多発性硬化症治療剤
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
EP1187612B1 (en) 2005-01-26
DE60017733D1 (de) 2005-03-03
WO2000074676A1 (en) 2000-12-14
JP2003522121A (ja) 2003-07-22
EP1552831B1 (en) 2009-01-07
DE60017733T2 (de) 2006-01-12
EP1552831A1 (en) 2005-07-13
ATE419851T1 (de) 2009-01-15
ATE287713T1 (de) 2005-02-15
EP1187612A1 (en) 2002-03-20
SI1187612T1 (en) 2005-06-30
PT1187612E (pt) 2005-05-31
AU5421900A (en) 2000-12-28
AU777537B2 (en) 2004-10-21
ES2235896T3 (es) 2005-07-16
CA2375874A1 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
WO1996032003A3 (en) Tetrahydroimidazopyridoindolediones and their use as medicaments
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
SI0797439T1 (en) Use of pramipexole as a neuroprotective agent
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
EP1193270A3 (en) Pyrrolobenzodiazepines
AP9901534A0 (en) Pharmaceutical formulations.
DE60112974D1 (en) Carbolinderivate
MX9700885A (es) Nuevas heteroariloxazolidinonas.
AU7031500A (en) Therapeutic quinazoline compounds
PL340836A1 (en) Novel compounds
IL196301A0 (en) Medicament for the treatment of hapatitis c
ZA977482B (en) 7α(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents.
SE9704546D0 (sv) Novel compounds
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
GB9415840D0 (en) Nozzle
DE60216233D1 (en) Carbolinderivate
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU3354895A (en) Novel medicinal use of 5ht3 antagonist
AU2001266575A1 (en) Chemical compounds
MX9708696A (es) Cefalosporinas antibacterianas.
ZA922297B (en) Crystalline tiababine monohydrate,its preparation and use
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
GB9907571D0 (en) Compounds
HUP9802634A3 (en) Use of benzimidazoles for the manufacture of pharmaceutical compositions for the treatment of leukemia

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIJK O, NL

Free format text: OLD OWNER(S): VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIKJK ONDERWIJS

RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 02 JUN 2020 BY COMPUTER PACKAGES INC

Effective date: 20130709

EXPY Patent expired